tirzepatide cardiovascular outcomes trial results august 2025 60-Second Journal Club: The SUMMIT examined of treatment with in patients with heart failure with preserved ejection fraction and obesity. Read the full trial Bridging the gap between GLP1-receptor

The GIP receptor is also activated by Mounjaro

However, researchers have compared the impact of both drugs from different studies and suggested that the higher doses (10mg and 15mg) of tirzepatide might reduce weight by 5.15kg more than 2mg of semaglutide

Nausea Nausea is the most commonly reported tirzepatide side effect

Semaglutide treatment at a dose of 1 mg weekly resulted in an 11 kg weight reduction over nine months, followed by an additional 7 kg weight loss over the next eleven months, once the dosage was elevated to 2 mg weekly

Most active players and API purchasers alike continue to source from China, making Chinese API supply a central variable in Indias GLP-1 economics regardless of how many domestic brands ultimately reach the market